Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
32 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Dong-A University Hospital
Busan, South Korea
- Kosin University College of Medicine - Kosin University Gospel Hospital (kugh)
Busan, South Korea
- Gyeongsang National University Hospital
Jinju, South Korea
- Korea University Medical Center (kumc)
Seoul, South Korea
- the Catholic University of Korea - Eunpyeong St. Mary'S Hospital
Seoul, South Korea
- Saint James'S University Hospital (sjuh) - St James'S Institute of Oncology
Leeds, United Kingdom
- the Clatterbridge Cancer Centre Nhs Foundation Trust
Liverpool, United Kingdom
- Barts Health Mhs Trust (barts and the London Nhs Trust) - St Bartholomew'S (barts) Hospital
London, United Kingdom
- the Royal Marsden Nhs Foundation Trust
London, United Kingdom
- East and North Hertfordshire Nhs Trust, Lister Hospital
Northwood, United Kingdom
- the Royal Marsden Nhs Foundation Trust
Sutton, United Kingdom
- the University of Arizona Cancer Center
Tucson, Arizona, United States
- University of California Irvine (uci)
Irvine, California, United States
- Tmpn Hunt Cancer Care
Torrance, California, United States
- University of California Los Angeles
Westwood, Los Angeles, California, United States
- University of Colorado Hospital (uch) Anschutz Cancer Pavilion
Aurora, Colorado, United States
- Miami Cancer Institute
Miami, Florida, United States
- Emory University Hospital Midtown
Atlanta, Georgia, United States
- University of Illinois Cancer Center
Chicago, Illinois, United States
- Amr Kansas City Oncology
Merriam, Kansas, United States
- University of Kansas Medical Center
Westwood, Kansas, United States
- Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana, United States
- University of Maryland Baltimore, Greenebaum Comprehensive Cancer Center
Baltimore, Maryland, United States
- Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, United States
- Morristown Medical Center
Morristown, New Jersey, United States
- Mount Sinai
New York, New York, United States
- Stony Brook Cancer Center
Stony Brook, New York, United States
- the Christ Hospital Cancer Center
Cincinnati, Ohio, United States
- University of Cincinnati Medical Center
Cincinnati, Ohio, United States
- University Hospitals Cleveland
Cleveland, Ohio, United States
- Prisma Health Cancer Institute
Greenville, South Carolina, United States
- Ut Southwestern Medical Center/simmons Comprehensive Cancer Center
Dallas, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 May 2023
- Primary completion
- 14 Aug 2025
- Completion
- 14 Aug 2025
- Last update posted
- 30 Jan 2026
- Registered enrollment
- 69
- Registry id
- NCT05814666
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.